127 related articles for article (PubMed ID: 29681495)
1. Corrigendum to "An altered REDOX environment, assisted by over-expression of fetal hemoglobins, protects from inflammatory colitis and reduces inflammatory cytokine expression" [Int. Immunopharmacol. 50 (2017) 69-76].
Gorczynski RM; Alexander C; Brandenburg K; Chen Z; Heini A; Neumann D; Mach JP; Rietschel ET; Terskikh A; Ulmer AJ; Yu K; Zahringer U; Khatri I
Int Immunopharmacol; 2018 Jun; 59():414. PubMed ID: 29681495
[No Abstract] [Full Text] [Related]
2. Corrigendum to "Emodin ameliorates ulcerative colitis by the flagellin-TLR5 dependent pathway in mice" [Int. Immunopharmacol. 59 (2018) 269-275].
Luo S; Deng X; Liu Q; Pan Z; Zhao Z; Zhou L; Luo X
Int Immunopharmacol; 2018 Sep; 62():337. PubMed ID: 29983242
[No Abstract] [Full Text] [Related]
3. Corrigendum to "Dioscin reduces lipopolysaccharide-induced inflammatory liver injury via regulating TLR4/MyD88 signal pathway" [Int. Immunopharmacol. 36 (2016) 132-141].
Yao H; Hu C; Yin L; Tao X; Xu L; Qi Y; Han X; Xu Y; Zhao Y; Wang C; Peng J
Int Immunopharmacol; 2019 Sep; 74():105786. PubMed ID: 31402320
[No Abstract] [Full Text] [Related]
4. Corrigendum to "Mangiferin corrects the imbalance of Th17/Treg cells in mice with TNBS-induced colitis" [Int. Immunopharmacol. (2016) 220-228].
Lim SM; Jeong JJ; Choi HS; Chang HB; Kim DH
Int Immunopharmacol; 2016 Sep; 38():468. PubMed ID: 27262502
[No Abstract] [Full Text] [Related]
5. Corrigendum to "Laquinimod ameliorates spontaneous colitis in interleukin-10-gene-deficient mice with improved barrier function" [Int. Immunopharmacol. (2015) 423-432].
Sun J; Shen X; Dong J; Zhao J; Zuo L; Wang H; Li Y; Zhu W; Gong J; Li J
Int Immunopharmacol; 2016 Jun; 35():341. PubMed ID: 27130814
[No Abstract] [Full Text] [Related]
6. Corrigendum to "Regulation of fetal hemoglobin expression during hematopoietic stem cell development and its importance in bone metabolism and osteoporosis" [Int. Immunopharmacol. 57 (2018) 112-120].
Kos O; Alexander C; Brandenburg K; Chen Z; Heini A; Heumann D; Khatri I; Mach JP; Rietschel ET; Terskikh A; Ulmer AJ; Waelli T; Yu K; Zähringer U; Gorczynski RM
Int Immunopharmacol; 2018 Jun; 59():413. PubMed ID: 29681496
[No Abstract] [Full Text] [Related]
7. Corrigendum to "Kujigamberol interferes with pro-inflammatory cytokine-induced expression of and N-glycan modifications to cell adhesion molecules at different stages in human umbilical vein endothelial cells" [Int. Immunopharmacol. 62 (2018) 313-325].
Fukuhara S; Tanigaki R; Kimura KI; Kataoka T
Int Immunopharmacol; 2021 Oct; 99():107992. PubMed ID: 34330057
[No Abstract] [Full Text] [Related]
8. Corrigendum to "Oleamide suppresses inflammatory responses in LPS-induced RAW264.7 murine macrophages and alleviates paw edema in a carrageenan-induced inflammatory rat model" [Int. Immunopharmacol. 56 (2018) 179-185].
Moon SM; Lee SA; Hong JH; Kim JS; Kim DK; Kim CS
Int Immunopharmacol; 2018 Jul; 60():246. PubMed ID: 29789261
[No Abstract] [Full Text] [Related]
9. Corrigendum to "Asiatic acid inhibits LPS-induced inflammatory response in human gingival fibroblasts" [Int. Immunopharmacol. 50(2017) 313-318].
Hao C; Wu B; Hou Z; Xie Q; Liao T; Wang T; Ma D
Int Immunopharmacol; 2019 Jul; 72():523. PubMed ID: 31080023
[No Abstract] [Full Text] [Related]
10. Corrigendum to "Isosteviol reduces acute inflammatory response after burn injurys by upregulating MMP9 in macrophages, leading to M2 polarization" [Int. Immunopharmacol. 106 (2022) 108609].
Qiao G; Ji W; Sun Z; Wang X; Li P; Jia H; Duan L; Qi F
Int Immunopharmacol; 2022 Dec; 113(Pt B):109414. PubMed ID: 36402673
[No Abstract] [Full Text] [Related]
11. Corrigendum to 'Farrerol protects dopaminergic neurons in a rat model of lipopolysaccharide-induced Parkinson's disease by suppressing the activation of the AKT and NF-κB signaling pathways'. [Int. Immunopharmacol. 75 (2019) 105739].
Li Y; Zeng Y; Meng T; Gao X; Huang B; He D; Ran X; Du J; Zhang Y; Fu S; Hu G
Int Immunopharmacol; 2020 Jul; 84():105962. PubMed ID: 31948857
[No Abstract] [Full Text] [Related]
12. Corrigendum to "Molsidomine alleviates acetic acid-induced colitis in rats by reducing oxidative stress, inflammation and apoptosis" [Int. Immunopharmacol. 99 (2021) 108005].
Mohamed NI; Suddek GM; El-Kashef DH
Int Immunopharmacol; 2022 Apr; 105():108575. PubMed ID: 35115257
[No Abstract] [Full Text] [Related]
13. Corrigendum to "Ameliorative effects of 3,4-oxo-isopropylidene-shikimic acid on experimental colitis and their mechanisms in rats" [Int. Immunopharmacol. 15(3) (2013) 524-531].
Xing J; You C; Dong K; Sun J; You H; Dong Y; Sun J
Int Immunopharmacol; 2023 Feb; 115():109700. PubMed ID: 36641893
[No Abstract] [Full Text] [Related]
14. Corrigendum to "Stereocalpin A inhibits the expression of adhesion molecules in activated vascular smooth muscle cells" [Int. Immunopharmacol. 12 (2012) 315-325].
Byeon HE; Park BK; Yim JH; Lee HK; Moon EY; Rhee DK; Pyo S
Int Immunopharmacol; 2019 Jan; 66():389. PubMed ID: 30503384
[No Abstract] [Full Text] [Related]
15. Corrigendum to "Sinomenine inhibits fibroblast-like synoviocyte proliferation by regulating α7nAChR expression via ERK/Egr-1 pathway" [Int. Immunopharmacol. 56 (2018) 65-70].
Yi L; Lyu YJ; Peng C; Zhu RL; Bai SS; Liu L; Wang PX; Zhou H; Dong Y
Int Immunopharmacol; 2018 Sep; 62():339. PubMed ID: 30007832
[No Abstract] [Full Text] [Related]
16. Corrigendum to "Isosteroid alkaloids with different chemical structures from Fritillariae cirrhosae bulbus alleviate LPS-induced inflammatory response in RAW 264.7 cells by MAPK signaling pathway" [Int. Immunopharmacol. 78 (2020) 106047].
Liu S; Yang T; Ming TW; Gaun TKW; Zhou T; Wang S; Ye B
Int Immunopharmacol; 2020 Jul; 84():106482. PubMed ID: 32278661
[No Abstract] [Full Text] [Related]
17. Corrigendum to "IDO1: An important immunotherapy target in cancer treatment" [Int. Immunopharmacol. 47 (2017) 70-77].
Li F; Zhang R; Li S; Liu J
Int Immunopharmacol; 2017 Aug; 49():231. PubMed ID: 28457914
[No Abstract] [Full Text] [Related]
18. Corrigendum to "PAD4 selective inhibitor TDFA protects lipopolysaccharide-induced acute lung injury by modulating nuclear p65 localization in epithelial cells" [Int. Immunopharmacol. 88 (2020) 106923].
Zhao X; Gu C; Wang Y
Int Immunopharmacol; 2023 Dec; 125(Pt B):111185. PubMed ID: 37957096
[No Abstract] [Full Text] [Related]
19. Corrigendum to "Pseudomonas aeruginosa-mannose sensitive hemagglutinin injection treated cytokine-induced killer cells combined with chemotherapy in the treatment of malignancies" [Int. Immunopharmacol. 51 (2017) 57-65].
Zhang C; Zhang Z; Wang L; Han J; Li F; Shen C; Li H; Huang L; Zhao X; Yue D; Huang J; Yan Y; Zhang Y
Int Immunopharmacol; 2022 Jan; 102():108356. PubMed ID: 34794888
[No Abstract] [Full Text] [Related]
20. Corrigendum to "2-Dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione, isolated from the root of Averrhoa carambola L., protects against diabetic kidney disease by inhibiting TLR4/TGFβ signaling pathway" [Int. Immunopharmacol. 80 (2020) 106120].
Zhang H; Lu S; Chen L; Huang X; Jiang L; Li Y; Liao P; Wu X; Zhou X; Qin L; Wei J; Huang R
Int Immunopharmacol; 2024 Mar; 129():111667. PubMed ID: 38350758
[No Abstract] [Full Text] [Related]
[Next] [New Search]
